 AI Found a Drug Faster Than Humans — And This Is Just the Beginning While the world debates neural networks for image generation, a quiet revolution is happening in biotech. In 2026, the first drug fully designed by artificial intelligence successfully passed Phase IIa clinical trials. Over 170+ AI projects are in development. What does this mean for business? - **Speed.** What used to take years and millions of dollars, AI analyzes in seconds — molecular structures, interactions, side effects. - **Accuracy.** Machine learning models predict compound efficacy with precision unattainable by traditional screening. - **Accessibility.** The FDA is already revising requirements for preclinical trials — fewer animal tests, more AI validation. This opens the market for small teams. What does ASI Biont have to do with it? We are building an ecosystem of AI agents that automate not only data analysis but entire business processes. Technologies that are transforming pharma today will change your industry tomorrow. - **A question for you:** How many years do you think it will take for AI agents to fully manage R&D processes without human involvement? → https://asibiont.com/